VYNE insider transaction filings
VYNE Therapeutics Inc. — 35 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-24. Screen VYNE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-24 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Tax withholding (F): 79,391 @ $0.90 | EDGAR |
| 2026-07-24 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Tax withholding (F): 22,516 @ $0.90 | EDGAR |
| 2026-07-24 | 4 | Stuart Iain — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 15,405 @ $0.90 | EDGAR |
| 2026-07-24 | 4 | Zeronda Tyler — CHIEF FINANCIAL OFFICER | Tax withholding (F): 22,516 @ $0.90 | EDGAR |
| 2026-07-02 | 4 | Zeronda Tyler — CHIEF FINANCIAL OFFICER | Tax withholding (F): 3,464 @ $0.65 | EDGAR |
| 2026-07-02 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Tax withholding (F): 3,464 @ $0.65 | EDGAR |
| 2026-07-02 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Tax withholding (F): 12,214 @ $0.65 | EDGAR |
| 2026-07-02 | 4 | Stuart Iain — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 2,370 @ $0.65 | EDGAR |
| 2026-06-02 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Grant/award (A): 30,791 @ $0.31 | EDGAR |
| 2026-04-02 | 4 | Zeronda Tyler — CHIEF FINANCIAL OFFICER | Tax withholding (F): 4,007 @ $0.60 | EDGAR |
| 2026-04-02 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Tax withholding (F): 4,007 @ $0.60 | EDGAR |
| 2026-04-02 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Tax withholding (F): 14,232 @ $0.60 | EDGAR |
| 2026-04-02 | 4 | Stuart Iain — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 2,876 @ $0.60 | EDGAR |
| 2026-01-05 | 4 | Zeronda Tyler — CHIEF FINANCIAL OFFICER | Tax withholding (F): 7,858 @ $0.58 | EDGAR |
| 2026-01-05 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Tax withholding (F): 3,579 @ $0.58 | EDGAR |
| 2026-01-05 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Tax withholding (F): 12,684 @ $0.58 | EDGAR |
| 2026-01-05 | 4 | Stuart Iain — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 2,448 @ $0.58 | EDGAR |
| 2025-12-15 | 4 | Little Elisabeth Sandoval — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Basta Steven L — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | BARBARI SHARON — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | LEPORE PATRICK G — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Zeronda Tyler — CHIEF FINANCIAL OFFICER | Tax withholding (F): 3,420 @ $0.34 | EDGAR |
| 2025-10-02 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Tax withholding (F): 3,581 @ $0.34 | EDGAR |
| 2025-10-02 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Tax withholding (F): 12,676 @ $0.34 | EDGAR |
| 2025-10-02 | 4 | Stuart Iain — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 2,453 @ $0.34 | EDGAR |
| 2025-07-02 | 4 | Zeronda Tyler — CHIEF FINANCIAL OFFICER | Tax withholding (F): 3,420 @ $1.65 | EDGAR |
| 2025-07-02 | 4 | Stuart Iain — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 2,453 @ $1.65 | EDGAR |
| 2025-07-02 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Tax withholding (F): 3,581 @ $1.65 | EDGAR |
| 2025-07-02 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Tax withholding (F): 12,676 @ $1.65 | EDGAR |
| 2025-06-03 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Grant/award (A): 1,145 @ $0.81 | EDGAR |
| 2025-06-03 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Grant/award (A): 8,681 @ $0.81 | EDGAR |
| 2025-04-02 | 4 | Zeronda Tyler — CHIEF FINANCIAL OFFICER | Tax withholding (F): 8,399 @ $1.58 | EDGAR |
| 2025-04-02 | 4 | Stuart Iain — CHIEF SCIENTIFIC OFFICER | Tax withholding (F): 6,044 @ $1.58 | EDGAR |
| 2025-04-02 | 4 | Harsch Mutya — CHIEF LEGAL OFFICER AND GC | Tax withholding (F): 8,828 @ $1.58 | EDGAR |
| 2025-04-02 | 4 | Domzalski David — PRESIDENT AND CEO, Director | Tax withholding (F): 30,498 @ $1.58 | EDGAR |
Recent 8-K events — VYNE Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-13 | 8-K/A | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.05 — Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VYNE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →